View Item 

Show simple item record

Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study

dc.contributor.authorVirtanen, J. K.en_US
dc.contributor.authorVoutilainen, S.en_US
dc.contributor.authorAlfthan, G.en_US
dc.contributor.authorKorhonen, M. J.en_US
dc.contributor.authorRissanen, Tiina H.en_US
dc.contributor.authorMursu, J.en_US
dc.contributor.authorKaplan, George A.en_US
dc.contributor.authorSalonen, Jukka T.en_US
dc.date.accessioned2010-06-01T20:06:38Z
dc.date.available2010-06-01T20:06:38Z
dc.date.issued2005-03en_US
dc.identifier.citationVIRTANEN, J. K.; VOUTILAINEN, S.; ALFTHAN, G.; KORHONEN, M. J.; RISSANEN, T. H.; MURSU, J.; KAPLAN, G. A.; SALONEN, J. T. (2005). "Homocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Study." Journal of Internal Medicine 257(3): 255-262. <http://hdl.handle.net/2027.42/73235>en_US
dc.identifier.issn0954-6820en_US
dc.identifier.issn1365-2796en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/73235
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=15715682&dopt=citationen_US
dc.format.extent107059 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Science Ltden_US
dc.rights2005 Blackwell Publishing Ltden_US
dc.subject.otherCardiovascular Diseaseen_US
dc.subject.otherHomocysteineen_US
dc.subject.otherInteractionen_US
dc.subject.otherProspective Studiesen_US
dc.subject.otherRisk Factorsen_US
dc.titleHomocysteine as a risk factor for CVD mortality in men with other CVD risk factors: the Kuopio Ischaemic Heart Disease Risk Factor (KIHD) Studyen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelInternal Medicine and Specialtiesen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USAen_US
dc.contributor.affiliationotherResearch Institute of Public Health, University of Kuopio, Kuopioen_US
dc.contributor.affiliationotherBiomarker Laboratory, National Public Health Institute, Helsinkien_US
dc.contributor.affiliationotherDepartment of Public Health and General Practice, University of Kuopio, Kuopio, Finlanden_US
dc.contributor.affiliationotherOy Jurilab Ltd, Kuopio, Finlanden_US
dc.identifier.pmid15715682en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/73235/1/j.1365-2796.2005.01450.x.pdf
dc.identifier.doi10.1111/j.1365-2796.2005.01450.xen_US
dc.identifier.sourceJournal of Internal Medicineen_US
dc.identifier.citedreferenceMangoni AA, Jackson SHD. Homocysteine and cardiovascular disease: current evidence and future prospects. Am J Med 2002; 112: 556 – 65.en_US
dc.identifier.citedreferenceVoutilainen S, Lakka TA, HÄmelahti P, LehtimÄki T, Poulsen HE, Salonen JT. Plasma total homocysteine concentration and the risk of acute coronary events: the Kuopio Ischaemic Heart Disease Risk Factor Study. J Intern Med 2000; 248: 217 – 22.en_US
dc.identifier.citedreferenceAlfthan G, Pekkanen J, Jauhiainen M et al. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 1994; 106: 9 – 19.en_US
dc.identifier.citedreferenceKnekt P, Reunanen A, Alfthan G et al. Hyperhomocystinemia. A risk factor or a consequence of coronary heart disease ? Arch Intern Med 2001; 161: 1589 – 94.en_US
dc.identifier.citedreferenceWoo KS, Chook P, Lolin Y et al. Hyperhomocysteinemia is a risk factor for arterial endothelial dysfunction in humans. Circulation 1997; 96: 2542 – 4.en_US
dc.identifier.citedreferenceWelch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042 – 50.en_US
dc.identifier.citedreferenceGlueck CJ, Shaw P, Land JE, Tracy T, Sieve-Smith L, Wang Y. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 1995; 75: 132 – 6.en_US
dc.identifier.citedreferenceSchlaich MP, John S, Jacobi J, Lackner KJ, Schmieder RE. Mildly elevated homocysteine concentrations impair endothelium dependent vasodilation in hypercholesterolemic patients. Atherosclerosis 2000; 153: 383 – 9.en_US
dc.identifier.citedreferenceAcevedo M, Pearce GL, Kottke-Marchant K, Sprecher DL. Elevated fibrinogen and homocysteine levels enhance the risk of mortality in patients from a high-risk preventive cardiology clinic. Arterioscler Thromb Vasc Biol 2002; 22: 1042 – 5.en_US
dc.identifier.citedreferenceO'Callaghan P, Meleady R, Fitzgerald T, Graham I, the European COMAC group. Smoking and plasma homocysteine. Eur Heart J 2002; 23: 1580 – 6.en_US
dc.identifier.citedreferenceNygard O, Refsum H, Ueland PM, Vollset SE. Major lifestyle determinants of plasma total homocysteine distribution: The Hordaland Homocysteine Study. Am J Clin Nutr 1998; 67: 263 – 70.en_US
dc.identifier.citedreferenceWalldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026 – 33.en_US
dc.identifier.citedreferenceSalonen JT. Is there a continuing need for longitudinal epidemiologic research? The Kuopio Ischaemic Heart Disease Risk Factor Study. Ann Clin Res 1988; 20: 46 – 50.en_US
dc.identifier.citedreferenceSchwab U, TÖrrÖnen A, Toppinen L et al. Betaine supplementation decreases plasma homocysteine concentrations but does not affect body weight, body composition, or resting energy expenditure in human subjects. Am J Clin Nutr 2002; 76: 961 – 7.en_US
dc.identifier.citedreferenceSalonen JT, NyyssÖnen K, Korpela H, Tuomilehto J, SeppÄnen R, Salonen R. High stored iron levels are associated with excess risk of myocardial infarction in eastern Finnish men. Circulation 1992; 86: 803 – 11.en_US
dc.identifier.citedreferenceSalonen JT, Salonen R, SeppÄnen K, Rauramaa R, Tuomilehto J. HDL, HDL2, and HDL3 subfraction, and the risk of acute myocardial infarction: a prospective population study in eastern Finnish men. Circulation 1991; 84: 129 – 39.en_US
dc.identifier.citedreferenceSalonen JT, SeppÄnen K, NyyssÖnen K et al. Intake of mercury from fish, lipid peroxidation and the risk of myocardial infarction and coronary, cardiovascular and any death in eastern Finnish men. Circulation 1995; 91: 645 – 55.en_US
dc.identifier.citedreferenceVollset SE, Refsum H, Tverdal A et al. Plasma total homocysteine and cardiovascular mortality: the Hordaland Homocysteine Study. Am J Clin Nutr 2001; 74: 130 – 6.en_US
dc.identifier.citedreferenceBostom AG, Silbershatz H, Rosenberg IH et al. Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingam men and women. Arch Intern Med 1999; 159: 1077 – 80.en_US
dc.identifier.citedreferenceBlacher J, Benetos A, Kirzin JM, Malejac A, Guize L, Safar ME. Relation of plasma total homocysteine to cardiovascular mortality in a French population. Am J Cardiol 2002; 90: 591 – 5.en_US
dc.identifier.citedreferenceGreenland S. Modelling and variable selection in epidemiologic analysis. Am J Public Health 1989; 79: 340 – 9.en_US
dc.identifier.citedreferencePekkanen J, Linn S, Heiss G et al. Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease. N Engl J Med 1990; 322: 1700 – 7.en_US
dc.identifier.citedreferenceErnst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956 – 63.en_US
dc.identifier.citedreferenceRoeters van Lennep JE, Westerveld HT, Erkelens DW, van der Wall EE. Risk factors for coronary heart disease: implications of gender. Cardiovasc Res 2002; 53: 538 – 49.en_US
dc.identifier.citedreferenceChowienczyk PJ, Watts GF, Cockkroft JR, Ritte JM. Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolemia. Lancet 1992; 340: 1430 – 2.en_US
dc.identifier.citedreferenceLeung WH, Lau CP, Wong CK. Beneficial effect of cholesterol-lowering therapy on coronary endothelium-dependent relaxation in hypercholesterolemic patients. Lancet 1993; 341: 1496 – 500.en_US
dc.identifier.citedreferenceVaudo G, Marchesi S, Siepi D et al. Relevance of homocysteine on brachial flow-mediated vasodilatation and carotid and femoral intima-media thickness in patients with hypercholesterolemia. Am J Cardiol 2004; 93: 1413 – 6.en_US
dc.identifier.citedreferenceMannucci PM. Recent progress in the pathophysiology of fibrinogen. Eur Heart J 1995; 16: 25 – 30.en_US
dc.identifier.citedreferenceNorio R. Diseases in Finland and Scandinavia. In: Rothscild HR, ed. Biocultural Aspects of Disease. Orlando, FL: Academic Press Inc., 1981; 358 – 415.en_US
dc.identifier.citedreferenceBrattstrÖm L, Wilcken DEL, Öhrvik J, Brudin L. Common methylenetetrahydrofolate reductase gene mutation leads to hyperhomocysteinemia but not to vascular disease. The result of a meta-analysis. Circulation 1998; 98: 2520 – 6.en_US
dc.identifier.citedreferenceRady PL, Tyring SK, Hudnall SD et al. Methylenetetrahydrofolate reductase (MTHFR): the incidence of mutations C677T and A1298C in the Ashkenazi Jewish population. Am J Med Genet 1999; 86: 380 – 4.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2796.2005.01450.x.pdf
Size:
104.5KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.